Comprehensive study identifies ZNF692 as a potential immune-related biomarker for colorectal cancer

Abstract

Abstract Although colorectal cancer (CRC) therapy has evolved significantly in recent years, the prognosis for individuals with advanced cancer is still bad. The molecular mechanisms of this illness and its therapeutic interventions require more research. In recent years, the role of ZNF692 in other tumour development has been heavily investigated, with one study showing that ZNF692 has distinct RNA splicing events within various types of hepatocellular carcinoma. Another study showed that patients with Lung adenocarcinoma with elevated ZNF692 had a poorer prognosis. These results suggest a potential link between ZNF692 and tumourigenesis as well as anti-tumour immunity. This study, which mined and analysed data from the The Cancer Genome Atlas (TCGA) database, discovered that ZNF692 was increased in the tumour cancer cells and tissues of CRC patients, and that high ZNF692 expression was substantially connected with distant metastasis, lymph node metastasis, and tumour stage in CRC patients. Cell lines showed that ZNF692 was abnormally and abundantly expressed in colorectal cancer tumour cells. Overall, the findings point to the possibility of using ZNF692 as a predictive biomarker for CRC.